Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comprehensive Compensation Urged For COVID-19 Vaccine Injuries In Korea

Rising Calls For Prompt Government Action

Executive Summary

Calls to more aggressively, comprehensively and quickly provide compensation for injuries thought to be linked to COVID-19 vaccinations have been made in South Korea, as possible adverse effect cases increase along with the national vaccination program.

You may also be interested in...



Compensation For COVID-19 Vaccine Injuries In India: Stark Fault Lines?

Scrip discusses with a cross-section of experts the complexities around pursuing compensation for COVID-19 vaccine-related injuries in India. Is there a case for ‘absolute liability’ for all injuries related to the two fast-tracked vaccines currently available, or alternatively a no-fault compensation program?

China Rush Over? Korean Firms Step Up To Seize Opportunities

Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.

Time To Shop? SK Sees ‘Biggest Opportunity’ For Biotech Investment

At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS144218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel